Charles River Laboratories International Inc.

Charles River Laboratories International Inc. CRL

Dividend Summary



There have not been any declared dividends recently.

Latest Dividends
Summary Previous dividend Next dividend
Status
Type
Per share
Declaration date
Ex-div date
Pay date

Enter the number of Charles River Laboratories International Inc. shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
We have not made any dividend predictions for Charles River Laboratories International Inc.
Dividend Yield Today
0.0%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Charles River Laboratories International Inc.
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
There are no Charles River Laboratories International Inc. dividends.
Year Amount Change
2006 0.0c
2007 0.0c
0%
2008 0.0c
0%
2009 0.0c
0%
2010 0.0c
0%
2011 0.0c
0%
2012 0.0c
0%
2013 0.0c
0%
2014 0.0c
0%
2015 0.0c
0%
2016 0.0c
0%
2017 0.0c
0%
2018 0.0c
0%
2019 0.0c
0%
2020 0.0c
0%
2021 0.0c
0%
2022 0.0c
0%
2023 0.0c
0%
2024 Sign Up Required

Charles River Laboratories International Inc. Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
0.0%
Optimized Yield
Sign Up Required
52 Week High
0.0% on 29 March 2023
52 Week Low
0.0% on 29 March 2023
Next Ex-Div-Date Countdown
Sign Up Required

About Charles River Laboratories International Inc.

Charles River Laboratories International, Inc. is a full service, non-clinical contract research company. The Company provides research models required in research and development of new drugs, devices, and therapies. The Company's segments include Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the research models, research model services, and research and GMP-compliant cells businesses. The DSA segment includes services required to take a drug through the early development process, including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions (Biologics), and Avian Vaccine Services (Avian).

Sector
Pharmaceuticals & Biotechnology
Country
United States
Share Price
$269.37 (yesterday's closing price)
Shares in Issue
51 million
Market Cap
$13.8bn
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
0
Market Indices
S&P 500
Home Page URL
https://www.criver.com/
No articles found